Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection.
Early anti-retroviral treatment (ART) in primary human immunodeficiency virus (HIV) infection (PHI) may have unique, restorative immunological and virological benefits which could enhance clinical outcomes. However, the sustainability of these HIV-specific immune responses and their impact on clinic...
| Main Authors: | , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado em: |
2008
|
| _version_ | 1826263240332541952 |
|---|---|
| author | Fox, J Scriba, T Robinson, N Weber, J Phillips, R Fidler, S |
| author_facet | Fox, J Scriba, T Robinson, N Weber, J Phillips, R Fidler, S |
| author_sort | Fox, J |
| collection | OXFORD |
| description | Early anti-retroviral treatment (ART) in primary human immunodeficiency virus (HIV) infection (PHI) may have unique, restorative immunological and virological benefits which could enhance clinical outcomes. However, the sustainability of these HIV-specific immune responses and their impact on clinical outcome remains unclear. We present a 3-year longitudinal clinical and immunological follow-up of a single-arm, prospective study assessing the long-term impact of a short-course of ART (SCART) during PHI. Twenty-eight subjects with defined PHI received 3 months of SCART at HIV-1 seroconversion. HIV-specific interferon-gamma+ CD4+ T cell responses, CD4 cell counts and plasma viral loads were assessed prospectively. Clinical outcome was defined as the time taken from PHI to a fall in CD4 cell counts <350 cells/mul on two or more occasions. Of 28 patients, 25 (89%) had detectable HIV-specific CD4+ helper responses at baseline. Five of 11 (45%) patients had preserved HIV-specific CD4+ responses 3 years after stopping SCART. Neither the presence nor magnitude of HIV-1-specific T helper responses either at baseline or 3 years following SCART cessation predicted clinical outcome. Rebound viraemia associated with stopping SCART did not diminish HIV-1-specific CD4+ responses. Long-term (>3 years) preservation of virus-specific CD4+ cells occurred in 45% of patients receiving SCART in PHI. There was no correlation between either the presence or magnitude of these responses and clinical outcome. |
| first_indexed | 2024-03-06T19:48:34Z |
| format | Journal article |
| id | oxford-uuid:23305421-e136-46a5-b109-7d4f573d5a87 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:48:34Z |
| publishDate | 2008 |
| record_format | dspace |
| spelling | oxford-uuid:23305421-e136-46a5-b109-7d4f573d5a872022-03-26T11:42:57ZHuman immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:23305421-e136-46a5-b109-7d4f573d5a87EnglishSymplectic Elements at Oxford2008Fox, JScriba, TRobinson, NWeber, JPhillips, RFidler, SEarly anti-retroviral treatment (ART) in primary human immunodeficiency virus (HIV) infection (PHI) may have unique, restorative immunological and virological benefits which could enhance clinical outcomes. However, the sustainability of these HIV-specific immune responses and their impact on clinical outcome remains unclear. We present a 3-year longitudinal clinical and immunological follow-up of a single-arm, prospective study assessing the long-term impact of a short-course of ART (SCART) during PHI. Twenty-eight subjects with defined PHI received 3 months of SCART at HIV-1 seroconversion. HIV-specific interferon-gamma+ CD4+ T cell responses, CD4 cell counts and plasma viral loads were assessed prospectively. Clinical outcome was defined as the time taken from PHI to a fall in CD4 cell counts <350 cells/mul on two or more occasions. Of 28 patients, 25 (89%) had detectable HIV-specific CD4+ helper responses at baseline. Five of 11 (45%) patients had preserved HIV-specific CD4+ responses 3 years after stopping SCART. Neither the presence nor magnitude of HIV-1-specific T helper responses either at baseline or 3 years following SCART cessation predicted clinical outcome. Rebound viraemia associated with stopping SCART did not diminish HIV-1-specific CD4+ responses. Long-term (>3 years) preservation of virus-specific CD4+ cells occurred in 45% of patients receiving SCART in PHI. There was no correlation between either the presence or magnitude of these responses and clinical outcome. |
| spellingShingle | Fox, J Scriba, T Robinson, N Weber, J Phillips, R Fidler, S Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. |
| title | Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. |
| title_full | Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. |
| title_fullStr | Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. |
| title_full_unstemmed | Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. |
| title_short | Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. |
| title_sort | human immunodeficiency virus hiv specific t helper responses fail to predict cd4 t cell decline following short course treatment at primary hiv 1 infection |
| work_keys_str_mv | AT foxj humanimmunodeficiencyvirushivspecificthelperresponsesfailtopredictcd4tcelldeclinefollowingshortcoursetreatmentatprimaryhiv1infection AT scribat humanimmunodeficiencyvirushivspecificthelperresponsesfailtopredictcd4tcelldeclinefollowingshortcoursetreatmentatprimaryhiv1infection AT robinsonn humanimmunodeficiencyvirushivspecificthelperresponsesfailtopredictcd4tcelldeclinefollowingshortcoursetreatmentatprimaryhiv1infection AT weberj humanimmunodeficiencyvirushivspecificthelperresponsesfailtopredictcd4tcelldeclinefollowingshortcoursetreatmentatprimaryhiv1infection AT phillipsr humanimmunodeficiencyvirushivspecificthelperresponsesfailtopredictcd4tcelldeclinefollowingshortcoursetreatmentatprimaryhiv1infection AT fidlers humanimmunodeficiencyvirushivspecificthelperresponsesfailtopredictcd4tcelldeclinefollowingshortcoursetreatmentatprimaryhiv1infection |